Title: Glipizide
CAS Registry Number: 29094-61-9
CAS Name: N-[2-[4-[[[(Cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide
Additional Names: 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]urea; glydiazinamide
Manufacturers' Codes: K-4024
Trademarks: Glibenese (Pfizer); Glucotrol (Pfizer); Mindiab (Pfizer); Minidiab (Pfizer); Ozidia (Pfizer)
Molecular Formula: C21H27N5O4S
Molecular Weight: 445.54
Percent Composition: C 56.61%, H 6.11%, N 15.72%, O 14.36%, S 7.20%
Literature References: Second generation sulfonylurea with hypoglycemic activity. Prepn: V. Ambrogi, W. Logemann, DE 2012138; eidem, US 3669966 (1970, 1972 both to Carlo Erba); Ambrogi et al., Arzneim.-Forsch. 21, 200 (1971). Pharmacology: eidem, ibid. 208; Marigo et al., ibid. 215. Metabolism: Goldaniga et al., ibid. 23, 242 (1973); Fuccella et al., J. Clin. Pharmacol. 13, 68 (1973). Toxicity: Ambrogi et al., Arzneim.-Forsch. 21, 208 (1971). Review of pharmacology and therapeutic efficacy: R. N. Brogden et al., Drugs 18, 329-353 (1979); H. E. Lebovitz, Pharmacotherapy 5, 63-77 (1985).
Properties: Crystals from ethanol, mp 208-209°. Also reported as mp 200-203°. LD50 in mice, rats (g/kg): >3, 1.2 i.p. (Ambrogi).
Melting point: mp 208-209°; mp 200-203°
Toxicity data: LD50 in mice, rats (g/kg): >3, 1.2 i.p. (Ambrogi)
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic; Sulfonylurea Derivatives. |